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Background: Enterotoxigenic Escherichia coli (ETEC) is an important cause of childhood diarrhea in resource-limited
regions. It is also an important cause of diarrhea in travellers to these areas.
To evaluate the protective efficacy of new ETEC vaccines that are under development, there is a need to increase
the capacity to undertake Phase IIB (human challenge) clinical trials and to develop suitable challenge models.
Methods: An in-hospital study was performed where fasting adult volunteers were experimentally infected with
1 × 106 to 1 × 109 colony forming units (CFUs) of the wild-type ETEC strain TW10598, which had been isolated from
a child with diarrhea in West Africa in 1997. We recorded symptoms and physical signs and measured serum
immune response to the TW10598 bacterium.
Results: We included 30 volunteers with mean age 22.8 (range 19.8, 27.4) years. The most common symptoms
were diarrhea (77%), abdominal pain (67%), nausea (63%), and abdominal cramping (53%). Seven subjects (23%)
experienced fever, none were hypotensive. Most of the volunteers responded with a substantial rise in the level of
serum IgA antibodies against the challenge strain.
Conclusions: We established the capacity and methods for safely undertaking challenge studies to measure the
efficacy of ETEC vaccine candidates in a hospital ward. Strain TW10598 elicited both clinical symptoms and an
immune response across the doses given.
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A recent case–control study on the burden and etiology
of moderate to severe diarrhea in children in low- and
middle-income countries (LMICs) demonstrated that
ETEC remains among the most important bacterial
pathogens and that ST-producing ETEC infection was
associated with increased case fatality [1]. There is a
need for a broadly protective ETEC vaccine [2], but a
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unless otherwise stated.an effective vaccine will be available [2,3], and despite
four decades’ of focused efforts, no effective ETEC vac-
cine has been developed. However, there is hope that ef-
fective vaccines may be developed, because natural
ETEC infections appear to protect against new infec-
tions [4,5].
Part of the challenge of developing effective ETEC vac-
cines is that, without considerable manipulation, human
ETEC do not effectively colonize and induce diarrhea in an-
imals. Human studies are needed to evaluate the immuno-
genicity and protective efficacy of new vaccines. Human
experimental infection and challenge studies are typically
performed in dedicated facilities that can house 10–20 vol-
unteers under “enteric precaution”, in Norway termed “in
isolation” during the phase when the volunteers are stillLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cluded in experimental ETEC infection studies is only
about 400 [6]. Undertaking such studies is resource-
demanding and few, often highly specialized, facilities can
perform them. This complicates the evaluation of new
ETEC vaccine candidates [7].
In human vaccine challenge studies (Phase IIB trials),
volunteers are usually allocated to receive a vaccine or pla-
cebo, followed by experimental infection with a live wild-
type ETEC strain after 2–3 months. The ETEC strains
most commonly used in such studies include H10407,
B7A, and E24377A [6]. These strains may not, however,
be good representatives for the ETEC types most com-
monly causing diarrhea in LMIC children. Strain H10407
has the rare ability of expressing all three ETEC toxins
(human heat-stable toxin (STh), porcine heat-stable toxin
(STp), and LT. Strain B7A has a rare toxin-colonization
factor combination (STh LT-Coli Surface antigen 6 [CS6]),
while E24377A appears to have an ancestral origin that
differs from other SThLT-CS1 CS3 strains [8].
To establish a human challenge model with a new ETEC
strain for use in clinical trials, there is first a need to do an
experimental infection study to ensure the safety of ingest-
ing the strain, and to determine the dose that would in-
duce a reliably high attack risk while minimizing the
likelihood of overwhelming an otherwise protective im-
mune response. To increase the capacity to perform Phase
IIB trials with human ETEC vaccines, and to introduce a
new challenge model for such studies, we undertook an
experimental infection study in a hospital ward at Hauke-
land University Hospital (HUH), Bergen, Norway, with an
epidemiologically relevant wild-type ETEC strain previ-
ously not used to experimentally infect volunteers.
Methods
Study subjects
Healthy 18–40 year-old subjects who had not traveled
to LMICs for the past 9 months were recruited by oral
and written information presented in a step-wise man-
ner. Two investigators informed potential volunteers in
plenary sessions. Those interested were given further in-
dividualized in-depth oral and written information. Fol-
lowing a final interview, subjects were required to
complete a written questionnaire to ensure that they
had understood the study rationale, potential benefits
and risks, and what procedures that were to be con-
ducted. We then obtained written informed consent.
Primary targets for this information were students at
the University of Bergen.
Challenge strain
Following a comprehensive phylogenetic analysis of hu-
man ETEC isolates [8,9], we selected strain TW10598
because it is a good representative for one of the majorETEC ancestral lineages that are often associated with
childhood diarrhea [8].
The O6:K15:H16 strain was isolated in 1997 from a
14 month old girl in Guinea-Bissau suffering from
diarrhea [10], and it is capable of producing STh and
LT, as well as the ETEC colonization factors CS2, CS3, and
CS21. It is sensitive to ciprofloxacin and trimethoprim-
sulfamethoxazole but resistant to ampicillin. A single-
colony pick of TW10598 had undergone genome sequen-
cing (GenBank BioProject ID: PRJNA59743) [9], and a
master cell bank and subsequent working cell bank (WCB)
were produced from this culture by the Inoculum Prepar-
ation Laboratory of the Center for Vaccine Development at
the University of Maryland School of Medicine. Frozen
WCB vials containing high-density bacterial growth
were shipped on dry-ice to HUH and checked for the
presence of ST and LT genes by PCR [11] before being
stored at −80°C in a temperature-monitored freezer.
Setting
The study was conducted between 29th of March 2011
and 31st of May 2013 in the Division for Infectious Dis-
eases (ID) at Department of Medicine at HUH, Bergen.
HUH is a 1,100-bed teaching hospital serving a popula-
tion of approximately 280,000 inhabitants. It is also a re-
ferral hospital for almost 1 million people in Western
Norway. The ID division runs two patient wards with
altogether 31 beds, 12 of which are in 10 cohort isola-
tion rooms. The volunteers were admitted primarily at
times of low prevalence of communicable diseases in the
local population.
Ethics approval
The study was approved by the Regional Committee for
Medical and Health Research Ethics, Health Region
West (REC-West, case number 2010/728-14).
Volunteer enrolment
We screened all eligible volunteers in the outpatient clinic
a median 7 (Range: 4, 46; Interquartile range: 6, 11) days
prior to infection, recorded their personal data and med-
ical history, and undertook a physical examination. Blood
specimens were collected five times from all subjects: At
the screening visit, within 24 hours of challenge (day 0),
and at days 7, 10, and 28. The specimens were used for
total blood cell counts and measurement of serum con-
centrations of electrolytes, creatinine, alanine aminotrans-
ferase (ALT), and glucose. Serum antibodies to hepatitis B
and hepatitis C virus were measured, and a combined
antibody/antigen assay for HIV infection was undertaken
at the screening visit. Urine tests, including a pregnancy
test in women, were performed, and an electrocardiogram
was taken. Stool specimens were collected for examination
for occult blood in feces (Hemo-Fec®, Diag Nor AS, Asker,
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opathogens in feces. The inclusion criteria were: a signed
informed consent, age between 18 and 40, completed
health questionnaire, stool culture without enteropatho-
gens, normal base-line blood tests, being able to be in iso-
lation for up to 10 days, and effective contraception in the
women. The exclusion criteria were: fever (≥38°C) during
the last 48 hours before study initiation, participation in
another clinical trial during the last 3 months, use of an
immunosuppressive agent, pregnancy, breastfeeding, and
positive fecal occult blood test. In addition, subjects were
excluded from the study if they had a history of any
chronic gastrointestinal conditions. From the day of ex-
perimental infection, the volunteers were hospitalized.
The volunteers were admitted to the Infectious Diseases
ward one or two at a time, and stayed in a cohort isolation
room suited for the study. The volunteers and the study
personnel adhered strictly to the hospital infection control
procedures.
Preparation of inocula
The inocula and the necessary media and buffers were
prepared by following a study-specific procedure. All steps
of the operator’s preparations were followed by at least
one observer to minimize the risk of errors. Bacterial cul-
tures were based on reagents free of animal products. Ma-
terial from WCB vials was streaked onto Luria-Bertani
(LB) agar, and six colonies apparent after over-night incu-
bation at 37°C in a temperature-monitored regular incuba-
tor were mixed together in phosphate-buffered saline
(PBS) and pipetted onto LB agar dishes to make a lawn.
After over-night incubation at 37°C, bacterial cells were
scraped from the agar surface and resuspended in PBS.
The bacteria were then pelleted by centrifugation at
2,000 × g for 5 min and resuspended in PBS. This proced-
ure was repeated three times. Cell density of the resulting
stock solution was determined by measuring the absorb-
ance at 600 nm with a spectrophotometer and comparing
the absorption with a pre-determined reference curve.
Based on these results, aliquots were subsequently diluted
in PBS to provide the correct bacterial cell concentration,
and thereby volume for the required dose. Before and after
administering the dose, an aliquot of the inoculum was
serially diluted in PBS and plated in triplicate onto LB
agar, and the actual dose given was back-calculated from
the colony counts following over-night incubation at 37°C.
Experimental infection
The volunteers fasted overnight, only being allowed to
drink water after midnight the day before challenge. One
minute before receiving the challenge strain, the subjects
drank 120 ml 1.33% bicarbonate buffer to neutralize gas-
tric acid. The dose of strain TW10598 was suspended in
2 ml PBS, to which 30 ml bicarbonate buffer was addedjust before drinking. The volunteers were allowed to eat
and drink normally 1 hour after ingesting the dose. The
first volunteers were given a low (1 × 106 CFU) dose, and
at least three volunteers received a given dose before we
decided whether to increase the dose 10-fold for the
next group of volunteers. The decision to increase the
dose was based on estimates on diarrheal attack risk de-
fined as the percentage of volunteers who got diarrhea,
as well as an assessment of their symptoms.
To clear the infection, the volunteers were given orally
2 × 500 mg ciprofloxacin daily for three days. This treat-
ment is generally used in ETEC challenge studies [12],
and is recommended by the Infectious Diseases Society
of America (IDSA) [13]. Indications for early initiation
of treatment were mild or moderate diarrhea accompan-
ied by clinical signs of dehydration or malaise, or moder-
ate or severe diarrhea according to definitions presented
below. Also, a volunteer would receive early treatment if
the study clinician decided antibiotic treatment was indi-
cated. If none of these criteria were fulfilled, the volun-
teer would receive ciprofloxacin from day 5.
Microbiological analyses of stool cultures were per-
formed daily. The challenge strain was detected from stool
specimens using PCR for the ST and LT genes. Stool speci-
mens were plated on Lactose agar for the identification of
E. coli. After aerobic incubation overnight at 35°C, a repre-
sentative selection of the bacteria were collected by swab-
bing the confluent part of the agar plate with a 1 μl
inoculating loop followed by suspension in 0.5 ml distilled
water. The sample was boiled for 10 minutes followed by
centrifugation at 16,000 × g for 5 minutes. Five μl of the
supernatant was used as PCR template and amplified in a
final volume of 20 μl reaction mixture containing LightCy-
cler® FastStart DNA MasterPLUS SybrGreen I (Roche Diag-
nostics GmbH, Germany) and 0,5 μM of each primer. The
primers used in this study were ST-geneforward (JW7): 5′-C
AC-CCG-GTA-CAR-GCA-GGA-TT-3′; ST-genereverse
(JW14): 5′- ATT-TTT-MTT-TCT-GTA-TTR-TCT-T-3′;
LT-A-geneforward (TW20): 5′- GGC-GAC-AGA-TTA-TA
C-CGT-GC-3′; and LT-A-genereverse (JW11): 5′-CGG-T
CT-CTA-TAT-TCC-CTG-TT-3′ [11]. PCRs were per-
formed using a LightCycler® 2.0 (Roche Diagnostics) in-
strument. An initial pre-incubation step at 95°C for 10
minutes was followed by 35 cycles of denaturation at 95°C
for 10 seconds, annealing at 55°C for 10 seconds and ex-
tension at 72°C for 10 seconds. After amplification, melt-
ing curve analysis at 65°C to 95°C was performed with a
temperature transition rate of 0.1°C/second to determine
the melting temperature (Tm) values for amplified PCR
products. A Tm of 79.0 ± 0.5°C and 82.0 ± 0.5°C was con-
sidered to indicate the presence of the STh and LT-A
gene, respectively. A negative control (distilled water) and
a positive control (extracted DNA from the challenge
strain were included in every PCR run. The efficiency of
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reason, we considered a stool specimen positive for strain
TW10598 if the ST and/or the LT-A gene was detected.
The isolation of a volunteer was suspended when 3
consecutive stool specimens were negative for ETEC. A
follow-up examination in the out-patient clinic was per-
formed at day 28, and a phone call at day 84 terminated
the follow-up period.
Clinical evaluation
During the period of hospitalization, volunteers were inter-
viewed and examined by a study physician once daily. Study
nurses and other clinical staff at the ward assessed the vol-
unteers a minimum of three times a day. Observations were
documented by use of individual Case Report Forms. Blood
pressure, heart rate, and oxygen saturation was assessed by
Criticare eQuality Vital Signs Monitor (Criticare Systems
Inc., Waukesha, WI, USA), and body temperature was
measured with the Light Touch LTX infrared thermometer
(Exergen Corp., Watertown, MA, USA).
Nausea, vomiting, abdominal pain or cramping, urgency,
bloating, flatulence, decreased appetite, constipation, fever,
chills, malaise, myalgias, headache, lightheadedness and
any organ system-related symptom were recorded and
graded daily as described elsewhere [12]. Symptoms were
considered elicited by the ETEC infection if they occurred
after challenge and before the end of the day the volunteer
received the first dose of ciprofloxacin.
Evaluation of stools and diarrhea was performed es-
sentially as described elsewhere [12].
The volunteers were considered to have diarrhea when
they passed 1 loose stool (≥grade-3) of ≥300 g or ≥2
loose stools (≥grade-3) totaling ≥200 g during any 48-
hour period. In cases where grade-1 or grade-2 stools
were observed within a diarrheal episode, we did not
consider these to represent diarrheal stools. If a volun-
teer experienced two separate diarrheal episodes, this
was considered to represent a single, continuous epi-
sode. For any diarrhea episode defined by a single diar-
rheal stool, the diarrhea duration was set to one hour.
Diarrhea was deemed to be mild in cases where, during
any 24 hour period of the episode, the subject experi-
enced 1 to 3 diarrheal stools with a total weight of ≤400
grams; moderate for 4 or 5 diarrheal stools, or a total
weight of 401–799 grams; and severe for ≥6 diarrheal
stools, or a total weight of ≥800 grams. Diarrhea would
also be considered severe in cases in need of intravenous
fluid treatment. If severity changed during an episode,
we reported the most severe grade.
Serum IgA antibodies against ETEC
Serum specimens were collected on days 0, 7, 10, and
28, and frozen at −80°C until it was used to measure IgA
directed against the challenge strain. Serum antibodiesagainst strain TW10598 were measured by flow cytome-
try with live bacteria [14], which were grown overnight,
harvested, washed in Hank’s balanced salt solution with
bovine serum albumin (HBSS/BSA), and adjusted to an
OD650 nm of 0.65 in HBSS/BSA. A serum specimen from
one of the participants with a high serum IgA antibody
level against strain TW10598 was included in each plate
to generate a standard curve. Fifty microliters of serum
at various dilutions in HBSS/BSA and 5 μl of bacterial
suspension were mixed by pipetting and incubated for
45 minutes at 37°C. They were then washed twice with
HBSS/BSA by centrifugation (850 × g for 3 min) and in-
cubated with anti-IgA R-phycoerythrin-(PE)-conjugate
goat anti-human IgA (2050–09, Southern Biotech, Bir-
mingham, AL, USA) at 1/100 in HBSS/BSA for 45 mi-
nutes. Finally, the bacteria were washed and suspended
in 100 μl HBSS/BSA supplemented with 10 μg/ml of the
DNA-binding fluorescent dye Hoechst 34580. The fluor-
escence intensity reflecting bound antibodies was read
by an Attune flow cytometer (Life Technologies, Carls-
bad, CA, USA), gating on the bacteria with combined
side scatter/Hoechst 34580 fluorescence. The standard
curve was drawn from the geometric mean PE fluores-
cence intensity (GMFI) of the various dilutions of the
standard serum which was assigned a value of 1,000 ar-
bitrary units (AU)/ml. The GMFI from the specimens
were interpolated on the standard curve with GraphPad
Prism software version 5 (GraphPad Software, Inc., San
Diego, CA). We calculated geometric mean serum level
of IgA directed against the challenge strain and the fold-
increase in geometric mean titers from day 0 to day 7,
10 and to 28.
Results
Volunteer characteristics
Thirty-two volunteers agreed to participate in the study.
Two subjects were excluded: one had an upper respira-
tory tract infection with fever the day before the
intended ETEC challenge, whereas asymptomatic infec-
tion with Campylobacter jejuni was detected in the other
volunteer. The volunteers entered the study in 21 separ-
ate groups. Of the 21 female and 9 male volunteers, 28
were medical students. Their mean age was 22.8 years
old (range: 19.8, 27.4; standard deviation: 1.95), and their
body mass indices ranged from 18.3 to 42.5 with a me-
dian 22.1 (interquartile range 20.7, 25.3) kg/m2.
Clinical response
The target doses for this study were 1 × 106, 1 × 107, 1 ×
108, and 1 × 109 CFU, while the actual doses given had
ranges 0.9–1.0 × 106, 0.7–1.4 × 107, 0.62–1.4 × 108, and
0.82–1.5 × 109 CFU, respectively. Twenty-three volun-
teers (77%) developed diarrhea, of which five had mild,
nine moderate, and nine severe episodes (Table 1). The
Table 1 Proportion of subjects with diarrhea, incubation period, stool output and episode duration among 30 volunteers experimentally infected with ETEC
strain TW10598 (STh LT-CS2 CS3 CS21; O6:K15:H16)
Target
dose (CFU)
No. of
volunteers
No. with
diarrhea
Attack risk Median severity Mean incubation
period, hours (range)
Mean 24 hrs maximum
stool output, grams (range)
Mean whole episode
stool output,
grams (range)
Mean episode
duration,
hrs (range)
Mean 24 hrs
maximum stool output,
count (range)
1 × 106 3 2 67% Mild-Moderate 60 (48–72) 416 (330–502) 613 (510–717) 37 (25–48) 2 (2–2)
1 × 107 8 5 63% Moderate 37 (9–70) 676 (407–1352) 877 (407–1842) 38 (6–72) 5 (3–9)
1 × 108 7 6 86% Moderate-Severe 38 (13–78) 965 (318–1790) 1466 (450–3608) 46 (18–78) 6.5 (3–13)
1 × 109 12 10 83% Moderate 30 (10–57) 538 (295–918) 687 (358–1315) 33 (1–106) 4.2 (1–9)
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erate to severe, and moderate for those who received
1 × 106, 1 × 107, 1 × 108, and 1 × 109 CFU of strain
TW10598, respectively.
The mean incubation period, i.e. the period from
challenge to the debut of symptoms, was 60 hours
among those receiving 1 × 106 CFU, and between 30 and
38 hours for those receiving higher doses. Diarrhea
duration ranged from 1 to 106 hours in the volunteers.
The number of bowel movements during diarrheal epi-
sodes ranged from 1 to 13, and stool weight ranged from
295 to 1,790 grams per 24 hours. While nurses provided
necessary fluids to prevent dehydration, the study physi-
cians decided that none of the volunteers required rehy-
dration with oral rehydration salts solution or with
intravenous fluids. ETEC was detected in stool speci-
mens of all volunteers prior to ciprofloxacin treatment.
The most frequent symptoms other than diarrhea were
nausea, abdominal pain, abdominal cramping, headache,
malaise, and decreased appetite (Table 2). Most symp-
toms were grade-1 and 2, none of the volunteers had
grade-4 or −5 symptoms, but two volunteers had grade-
3 abdominal pain, 1 had grade-3 abdominal cramps, and
one had grade-3 bloating. There were seven cases with
fever (all grade-1), and six with chills (5 grade-1 and 1
grade-2), but no case with signs of hypovolemia. No se-
vere adverse events were observed.Table 2 Symptoms and signs other than diarrhea in 30
volunteers experimentally infected with ETEC strain
TW10598
Target dose (CFU) 1 × 106 1 × 107 1 × 108 1 × 109
No. of volunteers 3 8 7 12
Nausea 1 (33%) 5 (63%) 5 (71%) 7 (58%)
Abdominal pain 0 4 (50%) 7 (100%) 7 (58%)
Abdominal cramping 0 1 (13%) 7 (100%) 6 (50%)
Excessive flatus 1 (33%) 1 (13%) 5 (71%) 5 (42%)
Decreased appetite 0 2 (25%) 5 (71%) 5 (42%)
Bloating 1 (33%) 0 0 6 (50%)
Vomiting 0 1 (13%) 0 2 (17%)
Constipation 0 0 0 1 (8%)
Headache 2 (67%) 2 (25%) 4 (57%) 5 (42%)
Malaise 0 2 (25%) 4 (57%) 5 (42%)
Fever 0 4 (50%) 1 (14%) 2 (17%)
Chills 0 1 (13%) 1 (14%) 4 (33%)
Myalgias 0 1 (13%) 0 4 (33%)
Lightheadedness 0 2 (25%) 0 1 (8%)
Hypovolemia 0 0 0 0Serum anti-TW105098 IgA response
In the pre-challenge sera (day 0), the geometric mean
level (GML) of IgA antibodies against TW10598 was
13.0 AU/ml (CI: 9.2, 18.5) (Figure 1). On day 7, 10 and
28 after challenge, the corresponding IgA antibody levels
were 136.8 AU/ml (CI: 90.0, 208.0), 314.4 AU/ml (CI:
217.9, 453.7) and 77.3 AU/ml (CI: 49.9, 119.7), respect-
ively. All but one participant exhibited at least a two-fold
response to the challenge strain. The low-responding vol-
unteer received a dose of 1 × 107 CFUs, did not develop
diarrhea, and was the only volunteer who did not experi-
ence any other symptoms from the infection. The geomet-
ric mean fold increase in the IgA level from day 0 to day
7, 10, and 28 was 10.5 (CI: 6.5, 16.9), 24.1 (CI: 15.2, 38.1),
and 5.9 (CI: 3.7, 9.5), respectively.
Discussion
In the present study, there were two specific aims that
may contribute to the development of ETEC vaccines.
First, as there is a lack of sites that are capable of per-
forming large experimental infection studies, including
Phase IIB trials, and, to the best of our knowledge, no fa-
cility for such studies in Scandinavia, we aimed at estab-
lishing such capacity at HUH. We undertook the study
in the hospital in a way that was compatible with every-
day work in the ID ward, and the method should be sub-
sequently applicable in similar institutions elsewhere.
The second aim was to develop a new challenge model
for ETEC, involving an epidemiologically relevant strain.
The present work describes the methods used to
establish competence and capacity to perform experi-
mental infection with ETEC within our hospital. HUH is
co-located with the University of Bergen, and, in our
setting, we chose to approach students, many of them
studying to become physicians. We believe these
students were likely to adequately comprehend all
information required to refuse or provide a genuinely
informed consent, as well as follow the study
procedures. As HUH has a restricted number of beds
under isolation, we had to rely on inclusion of a few
individuals at a time. This was possible in our student
population, as we could adjust their admission according
to the availability of cohort isolation rooms.
It may be challenging to free cohort isolation rooms in a
hospital such as ours. This problem was overcome by me-
ticulous planning and administration of their use. Thus,
volunteers were admitted primarily at times of low preva-
lence of communicable diseases, such as influenza, in our
community.
The study team ensured volunteer safety by careful
clinical monitoring similar to that presented in studies
taking place in dedicated units and prompt treatment
using procedures already established for care of patients
with severe invasive and non-invasive infections. The
Figure 1 Serum IgA antibody levels against the TW10598 ETEC challenge strain. Serum IgA antibody levels against live TW10598 bacteria
measured as arbitrary units (AU) by flow cytometry in 30 adult volunteers at different time points, pre (day 0) and post experimental infection.
Circles represent the IgA antibody level of each volunteer; horizontal lines indicate geometric means and 95% confidence intervals.
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care specialist and responsible for the evaluation of the
volunteers on a daily basis. Although in our study there
was no need for any advanced treatment modalities, the
safety level was probably equal to or higher than that of-
fered in most dedicated research units.
We found that our approach of undertaking the study in
a hospital ID ward was safe for the volunteers, and should
be applicable to other hospitals that lack research facilities
dedicated to challenge studies. It should be noted, how-
ever, that the approach probably is less efficient and more
costly and time-consuming than performing similar stud-
ies in such facilities. Further, while our approach is suitable
for establishing the safety and dose of experimental infec-
tion with a given ETEC strain, a dedicated unit would be
required to undertake a phase IIB vaccine trial.
The second goal of our study was to develop a new chal-
lenge model that could be used in future Phase IIB trials
for testing ETEC vaccine prototypes. For our model, we
elected a strain that has phenotypic traits and an ancestral
origin common to ETEC strains often found among LMIC
children with diarrhea [8]. In the present study, we found
that experimental infection with TW10598 was safe and
gave mild systemic symptoms and signs. We also found
that the strain was capable of eliciting a strong immune
response, in that most volunteers responded with a >20-
fold increase in serum IgA anti-TW105098 level from
day 0 to day 10. The response appeared to be strain spe-
cific because the volunteers did not respond to ETEC
strain H10407, which is ancestrally closely related to
TW10598 [8] but expresses a different serotype and
ETEC colonization factor (data not shown).In our study we administered doses used in other ETEC
challenge studies, i.e. 1 × 106 to 1 × 109 CFUs. In their re-
view of experimental infection, Porter et al. [6] found that
when limiting their analyses to the three most used ETEC
strains (H10407, B7A, and E24377A) the diarrhea attack
risk was dose-dependent. For these strains they found no
difference in diarrhea attack risks across any of the strains
at doses of 5 × 108 CFUs up to 1 × 1010, with an overall at-
tack risk of 87%. For a Phase IIB trial, we recommend
using a dose of 1 × 108 CFU, which gave an 86% attack risk
in our study. This dose is similar to what is normally used
in ETEC challenge studies [6]. From Table 1, it may seem
like volunteers who were given 108 CFU had more severe
diarrhea (frequency and volume) than those who were
given 109. However, the observations are based on data
from only 16 volunteers, and the differences are not statis-
tically significant (data not shown).
We found that most of the volunteers responded to
the infection with a substantial rise in the level of serum
IgA antibodies against the challenge strain. This is com-
parable to results obtained with LPS-based ELISA after
challenge with H10407 [12]. We used a method based
on flow-cytometry because it is faster than ELISA, and it
produces a better signal–to-background ratio with fewer
spurious readings.
Compared to other studies aimed at developing a new
ETEC challenge model, the number of included volun-
teers is high. The reason for this is that we wanted to es-
timate the attack risk and confirm the safety of the
experimental infection and use the data and specimens
collected during the study for further studies of immune
responses to ETEC infections.
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We describe a novel in-hospital experimental ETEC in-
fection study in healthy volunteers, in which ETEC
strain TW10598 elicited diarrhea, abdominal and consti-
tutional symptoms, and induced strong strain-specific
immune responses. The experimental infection was safe,
elicited moderate symptoms, and methods and capacity
needed to undertake Phase IIB trials were established.
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